The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS-wild type tumors who progressed on prior standard dose cetuximab and irinotecan.
Ahmad Ali Fora
No relevant relationships to disclose
Jeanne A McMahon
No relevant relationships to disclose
Greg Wilding
No relevant relationships to disclose
Adrienne E. Groman
No relevant relationships to disclose
Wen Wee Ma
No relevant relationships to disclose
Karen S. Romano
No relevant relationships to disclose
Marwan Fakih
No relevant relationships to disclose